Product Description
HS-10380 is a tablet drug used in the treatment of patients with schizophrenia (Sourced from: http://www.hspharm.com/upload/file/2022/03/09/8e5799bda87540e8bace6a33f887d9cd.pdf)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Hansoh Pharma
Company Location: Asia Pacific
Company Founding Year: 1995
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Schizophrenia
Phase 1: Alzheimer Disease|Symptoms of Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07759869 |
HS-10380-303 | P3 |
Not yet recruiting |
Schizophrenia |
2028-07-31 |
4% |
2026-08-13 |
Primary Endpoints|Treatments |
CTR20233666 |
CTR20233666 | P1 |
Completed |
Schizophrenia |
2024-09-13 |
2025-04-29 |
||
CTR20251425 |
CTR20251425 | P1 |
Recruiting |
Symptoms of Alzheimer Disease|Alzheimer Disease |
None |
2025-06-22 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20254981 |
CTR20254981 | P1 |
Completed |
Schizophrenia |
2026-01-28 |
2026-05-03 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT07550387 |
HS-10380-202 | P2 |
Completed |
Schizophrenia |
2026-01-02 |
2026-04-28 |
||
NCT07911787 |
HS-10380-301 | P3 |
Not yet recruiting |
Unknown |
2029-01-24 |
66% |
2026-11-04 |
Primary Endpoints|Treatments |
CTR20241250 |
CTR20241250 | P2 |
Completed |
Schizophrenia |
2026-01-19 |
2026-04-05 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|